Immunomonitoring of Stage IV Relapsed Neuroblastoma Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplantation

Rupert Handgretinger

Rupert Handgretinger

Immunomonitoring of Stage IV Relapsed Neuroblastoma Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplantation and Subsequent GD2 (ch14.18/CHO) Antibody Treatment

Christian Martin Seitz, Tim Flaadt, Markus Mezger, Anne-Marie Lang, Sebastian Michaelis, Marie Katz, Desiree´ Syring, Alexander Joechner, Armin Rabsteyn, Nikolai Siebert, Sascha Troschke-Meurer, Maxi Zumpe, Holger N. Lode, Sile F. Yang, Daniel Atar, Anna-Sophia Mast, Sophia Scheuermann, Florian Heubach, Rupert Handgretinger, Peter Lang, Patrick Schlegel

ORIGINAL RESEARCH
published: 22 July 2021
doi: 10.3389/fimmu.2021.690467
Frontiers in Immunology | www.frontiersin.org

2021-11-06T08:12:49+01:00November 6, 2021|Other article for therapists|

Share This Story, Choose Your Platform!

Go to Top